Telix Pharmaceuticals (TLX) Common Equity (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Common Equity of $415.4 million for Q4 2025, up 11.78% year-over-year from $371.6 million in Q4 2024, and up 11.78% quarter-over-quarter from $371.6 million in Q4 2024.
Telix Pharmaceuticals (TLX) Common Equity (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Common Equity for 3 consecutive years, with $415.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity rose 11.78% year-over-year to $415.4 million; the TTM figure through Dec 2025 stood at $415.4 million (up 11.78% YoY), while the FY2025 annual figure was $415.4 million, up 17.69% from the prior year.
- Common Equity rose to $415.4 million in Q4 2025 per TLX's latest filing, from $371.6 million in the prior quarter.
- Across five years, Common Equity topped out at $415.4 million in Q4 2025 and bottomed at $96.9 million in Q4 2023.
- Historically, Common Equity has averaged $294.6 million across 3 years, with a median of $371.6 million in 2024.
- Annual changes were most pronounced in 2024 — Common Equity jumped 283.32% — and 2025, when it grew 11.78%.
- Telix Pharmaceuticals' Common Equity stood at $96.9 million in 2023, then surged by 283.32% to $371.6 million in 2024, then gained by 11.78% to $415.4 million in 2025.
- Business Quant data shows TLX's Common Equity at $415.4 million in Q4 2025, $371.6 million in Q4 2024, and $96.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | 415.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 415.38 Mn |
| Dec 31, 2024 | 371.59 Mn |
| Dec 31, 2023 | 96.94 Mn |